Top

Reactions Weekly

Published in:

01-05-2023 | Ustekinumab | Case report

Dupilumab/ustekinumab

Treatment failure: case report

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Wang H, et al. 1546 Developing personalized therapy for Netherton syndrome based on skin gene expression analysis, cell profiling and inflammatory pathway characterization. Journal of Investigative Dermatology 143 (Suppl.): S265 abstr. 1546, No. 5, May 2023. Available from: URL: http://doi.org/10.1016/j.jid.2023.03.1564 [abstract]

Title: Dupilumab/ustekinumab
Treatment failure: case report
Publication date: 01-05-2023
Publisher: Springer International Publishing
Keywords: Ustekinumab
Dupilumab
Netherton Syndrome
Ixekizumab
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-38408-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dupilumab/ustekinumab

Treatment failure: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Immunosuppressants

Azathioprine/immune-globulin/prednisolone

Nafcillin

Pegfilgrastim

Plasma

Canadian product monograph for ella updated